| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Peroxisome proliferator-activated receptor alpha |
|---|
| Ligand | BDBM50122338 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_320733 (CHEMBL880389) |
|---|
| Kd | 1100±n/a nM |
|---|
| Citation |  Morphy, R; Rankovic, Z Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem48:6523-43 (2005) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Peroxisome proliferator-activated receptor alpha |
|---|
| Name: | Peroxisome proliferator-activated receptor alpha |
|---|
| Synonyms: | NR1C1 | Nuclear receptor subfamily 1 group C member 1 | PPAR | PPAR alpha/gamma | PPAR-alpha | PPARA | PPARA_HUMAN | Peroxisome Proliferator-Activated Receptor alpha | Peroxisome proliferator-activated receptor | Peroxisome proliferator-activated receptor alpha (PPAR alpha) |
|---|
| Type: | Enzyme |
|---|
| Mol. Mass.: | 52222.08 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | Q07869 |
|---|
| Residue: | 468 |
|---|
| Sequence: | MVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFGFTEYQYLGSC
PGSDGSVITDTLSPASSPSSVTYPVVPGSVDESPSGALNIECRICGDKASGYHYGVHACE
GCKGFFRRTIRLKLVYDKCDRSCKIQKKNRNKCQYCRFHKCLSVGMSHNAIRFGRMPRSE
KAKLKAEILTCEHDIEDSETADLKSLAKRIYEAYLKNFNMNKVKARVILSGKASNNPPFV
IHDMETLCMAEKTLVAKLVANGIQNKEAEVRIFHCCQCTSVETVTELTEFAKAIPGFANL
DLNDQVTLLKYGVYEAIFAMLSSVMNKDGMLVAYGNGFITREFLKSLRKPFCDIMEPKFD
FAMKFNALELDDSDISLFVAAIICCGDRPGLLNVGHIEKMQEGIVHVLRLHLQSNHPDDI
FLFPKLLQKMADLRQLVTEHAQLVQIIKKTESDAALHPLLQEIYRDMY
|
|
|
|---|
| BDBM50122338 |
|---|
| n/a |
|---|
| Name | BDBM50122338 |
|---|
| Synonyms: | (S)-3-[4-(3,3-Bis-biphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid | CHEMBL328455 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C38H34O4 |
|---|
| Mol. Mass. | 554.6742 |
|---|
| SMILES | [#6]-[#6]-[#8]-[#6@@H](-[#6]-c1ccc(-[#8]-[#6]\[#6]=[#6](/c2ccc(cc2)-c2ccccc2)-c2ccc(cc2)-c2ccccc2)cc1)-[#6](-[#8])=O |
|---|
| Structure | 
|
|---|
Search and Browse
